Navigation Links
ZEISS Ends Successful Fiscal Year 2012/13
Date:12/12/2013

STUTTGART, Germany, December 12, 2013 /PRNewswire/ --

Revenue Reaches New Record High

ZEISS has brought fiscal year 2012/13 to a successful conclusion (reporting date: 30 September 2013) with a new record high in revenue. The company generated revenue totaling EUR 4.190 billion (prior year: EUR 4.163 billion) and earnings (EBIT) of EUR 335 million (prior year: EUR 420 million). The Industrial Metrology and Medical Technology business groups recorded particularly strong growth. "In fiscal year 2012/13 we reached and partly exceeded our targets. ZEISS put in a good performance despite the challenging business environment and the weakness of the economy at the beginning of the year," said Dr. Michael Kaschke, President and CEO of Carl Zeiss AG. "We made no compromises in our multi-year investment program - the biggest ever in the company's history - but continued to implement it consistently and systematically."

The number of employees increased to 24,623 worldwide. The company increased its expenditure on research and development activities by five percent to EUR 411 million. Investments in property, plant and equipment totaled EUR 245 million.

More information at http://www.zeiss.com/press

ZEISS is an international leader in the fields of optics and optoelectronics. The more than 24,000 employees of ZEISS generated revenue of about 4.2 billion euros in fiscal year 2012/13. Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. ZEISS has been contributing to technological progress for more than 160 years. ZEISS develops and produces solutions for the semiconductor, automotive and mechanical engineering industries, biomedical research and medical technology, as well as eyeglass lenses, camera and cine lenses, binoculars and planetariums. ZEISS is present in over 40 countries around the globe with more than 40 production facilities, around 50 sales and service locations and over 20 research and development sites. Carl Zeiss AG is fully owned by the Carl Zeiss Stiftung (Carl Zeiss Foundation).

Press contact
ZEISS Group
Jörg Nitschke, Pressesprecher
Phone +49-07364-20-3242
Email: joerg.nitschke@zeiss.com


'/>"/>
SOURCE Carl Zeiss AG
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ophthalmic Instrumentation - Global Strategic Business Report - 2012 Featuring Abbott, Bausch & Lomb, Carl Zeiss and Others
2. Carl Zeiss continúa en ruta hacia el crecimiento futuro e inversión
3. Carl Zeiss Continues on Track to Further Growth and Investment
4. Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load; Cytoxan Preconditioning Successfully Enhances Engraftment
5. Orexigen Announces Successful Interim Analysis of Contrave Light Study
6. QRxPharma Announces Successful Completion Of A$7.5 Million Placement
7. WuXi AppTec Successfully Completes Its First 2000L Disposable Bioreactor Run Using an NS0 Cell Line, Marking an Industry Milestone
8. Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
9. Biocartis Presents the Successful use of Idylla[TM] for the Detection of the BRAF Mutation Status in Tumour Samples at the International AACR Congress (American Association for Cancer Research) in Boston
10. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
11. Overcoming Regional Marketplace Complexities to Successfully Launch a Global Brand Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... , May 4, 2017  Fortuna Fix Inc. (" ... to be the first to eliminate the need for embryonic ... cells to treat neurodegenerative diseases. Fortuna ... with Professor Michael Fehlings , MD, PhD; Father ... , MD, MPH; and Professor James Giordano , PhD. ...
(Date:5/4/2017)... Israel , May 4, 2017  DarioHealth Corp. ... mobile health and big data solutions, today announced that ... A&D Company, and STI Technologies Limited to lower diabetes ... immediately. Through STI,s innoviCares card, which is available throughout ... , DarioHealth customers will be eligible for additional savings ...
(Date:5/3/2017)...  Kalorama Information notes that transplant diagnostics is ... and this is projected to continue to 2021. ... or bone marrow transplants require histocompatibility between the ... this task. This according to a new report ... various PCR-based methodologies, Sanger sequencing and NGS used ...
Breaking Medicine Technology:
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... met this week to review more than eighty-nine grant submissions all vying ... emerging young scientists in the Parkinson’s field.     , The American Parkinson Disease Association ...
(Date:5/26/2017)... ... , ... Amir Qureshi, MD is the first physician in Arkansas to implant ... The Nuvectra™ Algovita SCS System has been FDA approved as a treatment option for ... to introduce the most powerful SCS system and the only stretchable lead on the ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... premium delicatessen foods, is sharing bold recipes for Memorial Day entertaining that are ... menus. , “Boar’s Head fresh sliced meats and cheeses featured in these ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... After raising ... Antzy Top gadget will continue to be available at a discounted crowdfunding price on ... with stress wherever they are, I also wanted to bring a fidget toy to ...
(Date:5/26/2017)... ... ... Lowe acts as host and helps educate and inform the public using the “Informed” ... reconnect with America as it explores some of the best places to hike and ... inventive new place for a family vacation, and have discovered hiking. Many will agree ...
Breaking Medicine News(10 mins):